Hemacord

The New York Blood Center (NYBC) is a prominent non-profit organization specializing in transfusion medicine, hematology research, and cellular therapies. It is best known in the biotech sector for its National Cord Blood Program, which developed Hemacord, the first hematopoietic progenitor cell-cord (HPC-C) product to receive FDA licensure. Hemacord is indicated for use in unrelated donor hematopoietic stem cell transplantation procedures for patients with disorders of the hematopoietic system. NYBC also operates the Lindsley F. Kimball Research Institute, focusing on areas such as infectious diseases, blood bank technology, and regenerative medicine. The organization serves as a critical supplier of blood products and a leader in stem cell research and development through its Comprehensive Cell Solutions division.